Don't miss out on these discounted products!
Act fast before the sale ends!
The following products are currently out of stock
Don't miss out on these discounted products!
Act fast before the sale ends!
The following products are currently out of stock
This section outlines the evolution and milestones of Behemothlabz from its founding in 2014 to its continued growth and innovation in 2024.
This section provides all our contact details, encouraging you to reach out for assistance or inquiries. It encompasses live chat, phone support, and email options, ensuring accessibility for all.
Discover all you need to know to partner with us and promote our products to earn rewards.
In our FAQs section, we have compiled answers to the questions we frequently receive. Quickly find information about our company, products, and policies. If you have any questions, you might find the answer here before reaching out to us directly.
In our Quality Control and Testing section, we uphold Behemothlabz’s Commitment to Quality by meticulously detailing our procedures.
Sign up Here for our regular newsletter and stay updated.
Women with hypoactive sexual desire disorder (HSDD) are the main subject of research for treatment with flibanserin. A chronic absence of sexual desire that upsets others or makes social interactions difficult is the hallmark of HSDD.
It is believed that flibanserin works by lowering serotonin levels in the brain and raising dopamine and norepinephrine levels. Some women with HSDD may find their sexual desire increases as a result. [R]
The FDA has approved the use of flibanserin, a multifunctional serotonin agonist and antagonist, to treat premenopausal women with hypoactive sexual desire disorder (HSDD). [R]
Dopamine and norepinephrine are released together with a decrease in serotonin as a result of their specific action on pyramidal neurons in the prefrontal cortex. [R]
The action of flibanserin is mediated by the enhancement of 5-HT1A receptors, which inhibits sexual inhibition, and the inhibition of 5-HT2A receptors, which inhibit sexual acceleration. By boosting brain activity in the excitatory parts and reducing the inhibitory response to sexual signals, this method of action is thought to increase sexual desire. Additionally, flibanserin inhibits P-glycoprotein, which may necessitate more frequent monitoring of medication concentrations with narrow therapeutic indices that are delivered by P-glycoprotein.
The medicine, which works on pyramidal neurons in the prefrontal cortex to release dopamine and norepinephrine and decrease serotonin, has been licensed by the FDA for the treatment of HSDD in premenopausal women. It interacts with cytochrome P450 isoenzymes and exhibits kinetics that is linear and dosage proportionate. Alcohol should be avoided when taking flibanserin as side effects could arise. [R] [R][R]
Clinical trials and other research have been carried out to evaluate the efficacy and safety of flibanserin in treating HSDD in premenopausal women. All of these studies have demonstrated that Flibanserin can improve the frequency of pleasurable sexual encounters while lowering the pain brought on by low sexual desire.
Although flibanserin has been proven to be generally safe and well-tolerated, there are some possible adverse effects, including nausea, exhaustion, and dizziness. When used with alcohol or other drugs that depress the central nervous system, flibanserin has the potential to produce low blood flow pressure and fainting.
The FDA approved Flibanserin for human consumption.
In order to treat acquired global hypoactive sexual desire disorder (HSDD) in premenopausal women, FDA approves flibanserin. It functions by adjusting the brain’s concentrations of dopamine, noradrenaline, and serotonin. The Distress Scale-Revised (FSDS-R) Total Score significantly improved in three randomized, double-blinded, placebo-controlled investigations of flibanserin in premenopausal research subjects with HSDD. [R][R]
Another study wherein three randomized, double-blind, placebo-controlled trials involving 2,400 research subjects of reproductive age examined the efficacy of flibanserin. For 24 weeks, research subjects were given 100 mg of flibanserin or a placebo at night time. The number of satisfying sexual events (SSEs) each month as it changed from baseline to the end of treatment was the main result. In all three trials, flibanserin markedly increased the number of SSEs per month compared to placebo. The treatment’s impact was, however, moderate, and several research subject has no change in their ability or desire to engage in sexual activity. Flibanserin was linked to a higher risk of side effects, such as nausea, drowsiness, and vertigo. [R]
In animal models such as rats, another study aimed to assess the acute and chronic dose-response effects of flibanserin on measures of sexual desire and copulation in ovariectomized rats primed with estradiol benzoate (EB) alone or in combination with progesterone (P). The findings demonstrated that chronic flibanserin administration promoted appetitive sexual behaviors in OVX female rats primed with EB + P or EB alone, but not acute flibanserin treatment. These findings are consistent with previous reports that solicitations in female rats are a predictive animal model of human female sexual desire. [R]
It has been demonstrated that flibanserin somewhat increases some research subjects’ sexual enjoyment. It is not, however, permitted for use as a contraceptive. Oral contraceptive use, according to research, may help certain research subjects’ HSDD. It is crucial to remember that combining the use of flibanserin and oral contraceptives may raise the risk of specific side effects and should only be done with a doctor’s approval. [R] [R] [R]
Recently, it was shown that the novel substance flibanserin had antidepressant-like effects in animals. The rat prefrontal cortex (PFC), which is a region thought to be important in the regulation of mood and emotionality, was the subject of this investigation as we looked into whether the drug affected the extracellular levels of dopamine (DA), noradrenaline (NA), and serotonin (5-HT). According to in vivo microdialysis, flibanserin (0.5, 1, 2 mg/kg, i.p.) enhanced the extracellular concentrations of DA and NA and lowered the concentration of 5-HT in the PFC of freely moving rats. Following drug delivery, flibanserin had a dose-dependent effect on 5-HT that lasted for at least two hours. PCPA (p-chlorophenylalanine)’s suppression of 5-HT production had no effect on the rise in DA and NA brought on by flibanserin. The drop in 5-HT and rise in DA and NA caused by flibanserin were totally stopped by the specific 5-HT1A receptor antagonist WAY100,635. According to our findings, flibanserin elevates DA and NA levels in the PFC through a mechanism unrelated to serotonergic neuron activation or suppression of 5-HT production, and the effect on 5-HT is mediated by blocking 5-HT1A receptors. [R]
In a randomized, double-blind, placebo-controlled trial, the effectiveness and safety of flibanserin for the treatment of hypoactive sexual drive disorder in research subjects were assessed. flibanserin 100 mg/day or placebo was administered randomly to 1,378 premenopausal research subjects with HSDD for 24 weeks. The number of satisfying sexual events (SSEs) each month as it changed from baseline to the end of treatment was the main result. When compared to a placebo, flibanserin considerably raised the number of SSEs each month and also significantly improved the desire and distress scores on other measures of sexual function. However, flibanserin was linked to a higher risk of adverse events, such as nausea, somnolence, and dizziness, and some research subjects stopped taking it as a result. [R]
Flibanserin frequently causes side symptoms including drowsiness, somnolence, nausea, weariness, dry mouth, sleeplessness, and syncope. Flibanserin has the potential to lead to CNS depression, sedation, and somnolence. Before using Flibanserin, patients should abstain from alcohol, and they shouldn’t take it after more than three standard drinks. Adverse responses are possible, and they frequently lead to withdrawal. The most frequent causes are dizziness, nausea, sleeplessness, somnolence, and anxiety. In order to make sure the drug is suitable and safe for the patient, it is crucial to speak with a healthcare practitioner. [R] [R][R]
The average terminal half-life of Flibanserin is approximately 11 hours. [R] [R] [R]
Flibanserin is legal and approved by the FDA for use in treating hypoactive sexual desire disorder (HSDD) in premenopausal women. The drug was approved in 2015.[R][R]
Behemoth Labz is the best place to buy Flibanserin online.
We have been around since 2014, supplying the highest-quality research compounds money can buy. Our products come with a 100% satisfaction guarantee, free shipping, and a money-back guarantee.
While both Flibanserin and Viagra are used to treat sexual dysfunction. The mechanisms of action of Viagra and flibanserin are distinct. Flibanserin is a drug that increases sexual arousal and sex drive by focusing on specific neurotransmitters in the brain. The vaginal region’s blood flow is not intended to be boosted by it.
On the other side, Viagra is a drug that is intended to treat men’s erectile dysfunction. It functions by boosting blood flow to the penis, which aids in achieving and sustaining an erection. It is also an FDA-approved Viagra.
As a result, it is incorrect to generalize that Viagra or flibanserin in increasing blood flow. The drug company designed them to address specific conditions, and their mechanisms of action have an impact on how they behave.
Flibanserin should be stored in a closed container at room temperature, away from heat, moisture, and direct light, and should be kept from freezing. Furthermore, it should be kept out of reach of children. The medication should be stored in a dry and well-ventilated place, and the recommended storage temperature is between 20°C to 25°C. [R] [R][R]
Flibanserin, also known as Addyi, is a drug used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women. It is believed to work by increasing dopamine and norepinephrine levels in the brain while decreasing serotonin levels, thereby increasing sexual desire. Clinical trials have shown that Flibanserin can improve the frequency of pleasurable sexual encounters and lower the pain caused by low sexual desire. However, it may have potential adverse effects such as nausea, exhaustion, and dizziness, and it should not be used with alcohol or other drugs that depress the central nervous system. Additionally, Flibanserin inhibits P-glycoprotein, which may require more frequent monitoring of medication concentrations with narrow therapeutic indices that are delivered by P-glycoprotein. Flibanserin is not approved for use as a contraceptive and may raise the risk of specific side effects if combined with oral contraceptives. Finally, recent studies have suggested that Flibanserin has potential antidepressant-like effects in animals by enhancing the extracellular concentrations of dopamine and norepinephrine while lowering the concentration of serotonin in the prefrontal cortex.
Please make sure you go through the Terms and Conditions, and please familiarize yourself with it as it is important. Please research the scientific uses of this product before making any purchases. Make note that the packaging and labels of the product may differ from those shown on the website.
Buying the product means you agree with our Terms and Conditions. You can contact our awesome customer service team at [email protected] if you are not fully satisfied with the product. Customer satisfaction is our number one priority!
ATTENTION: All BehemothLabz products are strictly for LABORATORY AND RESEARCH PURPOSES ONLY. They are not to be used for any human or veterinary purposes.
Reviews
There are no reviews yet